6:25 PM
Dec 12, 2012
 |  BC Extra  |  Clinical News

Lilly planning additional solanezumab trial

Eli Lilly and Co. (NYSE:LLY) said it will start by no later than 3Q13 an additional Phase III trial of IV solanezumab, an antibody binding to soluble beta amyloid, in patients with mild Alzheimer's disease. The pharma is still finalizing trial details. Lilly...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >